Professional edition active

DAA Combination Therapies for the Treatment of HCV

Direct Acting Antiviral Combination

Genotype

Duration of Treatment

Sofosbuvir/LedipasvirSofosbuvir/Ledipasvir

1, 4, 5, 6

8–24 weeks depending on patient population

Sofosbuvir/VelpatasvirSofosbuvir/Velpatasvir

1–6

12 weeks

Glecaprevir/PibrentasvirGlecaprevir/Pibrentasvir

1–6

8–16 weeks depending on patient population

Elbasvir/GrazoprevirElbasvir/Grazoprevir

1, 4

12–16 weeks depending on patient population

Sofosbuvir/Velpatasvir/VoxilaprevirSofosbuvir/Velpatasvir/Voxilaprevir

1–6

12 weeks

In these topics